European Commission approves extension of indication for Otsuka’s JINARC® ▼ (tolvaptan) to include treatment of ADPKD patients with advanced chronic kidney disease (CKD stage 4)1
Otsuka Pharmaceutical Europe Ltd. (OPEL) today announced that the European Commission has approved an extension of indication for JINARC ® (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease (ADPKD).1 JINARC® was approved in 2015 for the treatment of ADPKD in adults with CKD stage 1-3 at initiation of treatment and evidence of rapidly progressing disease.1 The decision to include stage 4 within the JINARC ® licence comes following the submission of additional data from the REPRISE study that supported the safety and efficacy of this treatment in patients with more advanced renal disease.
Data from the tolvaptan clinical trial programme were submitted to the European Commission, including the REPRISE2 study, which supported the efficacy and tolerability of JINARC ® observed in the previous TEMPO 3:43 and TEMPO 4:44 studies. These studies confirmed that tolvaptan slows the progression of ADPKD in patients with earlier (CKD stage 1-3) as well as those with advanced (CKD stage 4) stages of disease.2,3,4
JINARC ® is a selective vasopressin-2-receptor antagonist containing the active substance tolvaptan. It blocks receptors in the kidneys that are responsible for the action of vasopressin. Suppression of vasopressin activity reduces the formation and enlargement of cysts and protects kidney function in patients with polycystic kidney disease (PKD). ADPKD is a progressive genetic disorder affecting the kidneys, in which fluid-filled cysts develop in the kidneys over time, enlarging these organs and reducing their ability to function normally, leading to kidney failure in most patients.5 ADPKD is the most common type of PKD, and is the fourth leading cause of kidney failure.5,6 Approximately 70% of European patients with ADPKD progress to end-stage renal disease (ESRD) at a median age of 58 years.7
JINARC® is the only pharmacological treatment indicated to slow the progression of cyst development and renal insufficiency in ADPKD patients with evidence of rapidly progressing disease.
▼ This medicinal product is subject to additional patient monitoring. This will allow quick identification of new safety information. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their relevant local bodies.
Notes to Editors
About the JINARC ® studies
The REPRISE study was a phase 3b, multi-centre, randomised-withdrawal, placebo-controlled, double blind trial involving 1,370 subjects, comparing the efficacy and safety of tolvaptan (45 to 120 mg/day, split-dose) in ADPKD patients with CKD between late stage 2 to early stage 4 (eGFR between 25 and 65 mL/min/1.73 m2). Results showed that tolvaptan significantly reduced the rate of estimated Glomerular Filtration Rate (eGFR) decline by 35% compared to placebo over 1 year (N=1,370; difference in eGFR change: is 1.27 mL/min/1.73 m2, 95% CI 0.86-1.68, P<0.001).2,8
TEMPO 3:4 was a phase 3, multi-centre, double-blind, randomised, placebo-controlled, parallel-arm 36-month trial involving 1,445 patients to determine long-term safety and efficacy of oral tolvaptan tablet regimens in adults with ADPKD. Results showed that tolvaptan slowed Total Kidney Volume (TKV) growth and eGFR decline, relative to placebo.3
TEMPO 4:4 was a two-year multi-centre, open-label extension study of TEMPO 3:4, including 871 subjects, designed to provide an additional 2 years data on the long-term efficacy and safety of tolvaptan in ADPKD. Although TEMPO 4:4 did not meet its primary TKV endpoint, results were suggestive of a disease-modifying effect on the secondary endpoint of renal function (eGFR).4
The results of the REPRISE study suggest that although the overall risks versus benefits will need to be carefully considered before initiating treatments in patients with late-stage ADPKD, in selected patients with CKD stage 4, JINARC ® has a positive benefit/risk balance.9,10
Treatment must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has R&D programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in Europe in 1974 and today Otsuka Pharmaceutical Europe Ltd. employs approximately 600 people who channel their passion and energy into converting the latest science into much-needed medicines.
Otsuka Pharmaceutical Company is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 46,000 people worldwide and had consolidated sales of approximately EUR 9.8 billion in 2017.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en. Learn more about Otsuka in Europe at www.otsuka-europe.com or visit our Twitter page www.twitter.com/otsukaeurope.
1 European Commission. Commission implementing decision of 26.7.2018 amending the marketing authorization granted by Decision C(2015)3676(final) for “Jinarc – tolvaptan”, a medicinal product for human use. 2018.
2 Torres V et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377(20): 1930-42.
3 Torres V et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367(25): 2407-18.
4 Torres V et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2017; 32(7): 1262.
5 National Kidney Foundation (2017) Polycystic Kidney Disease. Available at: https://www.kidney.org/atoz/content/polycystic [Last accessed: July 2018]
6 Chebib F et al. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis. May 2016; 67(5): 792-810.
7 Spithoven EM et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 2014; 86: 1244-52.
8 OPDC Data on file 2017
9 European Medicines Agency. CHMP extension of indication variation assessment report. 2018.
10 European Medicines Agency. Extension of indication variation. Final clinical assessment report. 2018.
Head of Communications – Europe
Otsuka Pharmaceutical Europe Ltd.
+44 (0)203 7475000
Leader, Pharmaceutical Public Relations
Otsuka Pharmaceutical Co., Ltd.
+81 3 6361 7379
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
JPMorgan Chase Bank Announces Initial Exchange Price for the Cash-Settled Exchangeable Bonds into Dufry Due 202117.10.2018 21:13 | Tiedote
Following the placement on 10 October 2018, JPMorgan Chase Bank, N.A. today announces the initial exchange price of the cash-settled exchangeable bonds due 2021 (the “Bonds”) in aggregate principal amount of USD 205 million, referable to ordinary shares of Dufry AG (the “Shares”) The initial exchange price of the Bonds has been set at CHF 134.8547, representing a 25% premium over the reference share price of CHF 107.8837, which was determined in the manner described in the press announcements released on 10 October 2018 and based on a Reference FX Rate of CHF:USD 1.0096. Settlement and delivery of the Bonds took place today. About JPMorgan Chase & Co. JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.6 trillion and operations worldwide. The firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Indu
Mouser Electronics and Grant Imahara Launch New Series All Things IoT about Technology Redefining How We Live17.10.2018 18:40 | Tiedote
Mouser Electronics Inc. and celebrity engineer Grant Imahara today released a new video introducing All Things IoT, the latest series in Mouser’s award-winning Empowering Innovation Together™ program. The All Things IoT series is sponsored by Mouser’s valued suppliers Digi International, Maxim Integrated, Murata and TE Connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005655/en/ Global distributor Mouser Electronics and engineer spokesperson Grant Imahara team up to launch All Things IoT, the latest series in Mouser's Empowering Innovation Together program. The new series kicks off with Imahara's visit to the HPE IoT Innovation Lab in Houston to learn how the Internet of Things is impacting our workplaces and cities. To learn more, visit www.mouser.com/empowering-innovation/all-things-iot. (Photo: Business Wire) In the new video, Imahara and Mouser explore the complexities of life rooted in the Internet of T
Telefónica Deutschland Selects Mavenir vIMS for Deployment on ‘UNICA’17.10.2018 17:59 | Tiedote
Mavenir, the leader in accelerating and redefining mobile network economics transformation for Communications Service Providers (CSPs), today announced that Telefónica Deutschland (FWB: O2D) is deploying Mavenir’s virtualized IMS solution (vIMS) for VoLTE and VoWiFi in their nationwide UNICA Data Centers Infrastructure, which is based on the Telefónica Group blueprint for Network Functions Virtualization (NFV) architecture. The solution will support mobile and fixed services for more than 45 million customer connections. The NFV environment is based on OpenStack® and will include automation, life cycle management and integration with Management and Orchestration (MANO) capabilities from the Telefónica UNICA platform. The Mavenir advanced vIMS solution will enable automation from day one and will support existing voice digital services as well as the launch of new services. As a software-based company leading the Telco NFV industry, Mavenir is a perfect match with Telefónica UNICA NFV s
Lenovo and Scale Computing Collaborate to Solve Edge Infrastructure Challenges for Retailers17.10.2018 17:34 | Tiedote
Lenovo (HKSE: 992) (ADR: LNVGY), a Global Fortune 500 company and a technology leader in Intelligent Transformation, and Scale Computing, a market leader in intelligent edge solutions, today announced a global partnership and a new joint product providing a solution for edge infrastructure for global retailers, distributed enterprises and small and medium-sized businesses. The solution is ideal for highly distributed, on-premise environments, such as retail stores or bank branches, with multiple locations managed by the enterprise from a central location. Lenovo’s broad range of servers combined with efficient, intelligent edge infrastructure software from Scale Computing deliver a simple, self-healing, highly-available platform for running applications at the edge or hybrid edge-and-cloud. The Scale Computing HC3 Edge Platform on Lenovo Servers replaces traditional complex and expensive on-premise infrastructure with a modern solution optimized for environments where application uptim
As Hilton Nears 100-Year Milestone, New Research Uncovers a World-Changing Impact17.10.2018 16:24 | Tiedote
As Hilton (NYSE: HLT) heads toward a milestone 100th anniversary in 2019, best-selling author and Stanford Business professor Chip Heath will unveil the impact the first global hotel company has had around the world in a new book titled The Hilton Effect. Business author Karla Starr joined him in the examination of the company founded by Conrad Hilton, a dreamer who aspired to create much more than just a comfortable place to sleep. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005486/en/ As Hilton nears 100-year milestone, new research uncovers a world-changing impact. (Graphic: Business Wire) Over the last century, Hilton has grown from a single hotel in Cisco, Texas, to nearly 5,500 hotels and 14 brands in 106 countries and territories. Hilton’s hotels have hosted more than 3 billion guests since 1919 and enlisted nearly 10 million Team Members in the company’s mission to fill the Earth with the light and warmth of
Infovista Announces Channel Go-to-Market Strategy for 5G, Application-Aware SD-WAN Solutions17.10.2018 16:00 | Tiedote
Reinforcing its commitment to the channel to deliver its industry-leading 5G, application-aware SD-WAN and network testing solutions to market, Infovista, the leader in modern network performance, today announced its go-to-market strategy is “all indirect, all the time.” To accelerate its global channel strategy, Infovista has hired industry veteran Jon Howes as senior vice president, global channel sales. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005042/en/ Jon Howes, Senior Vice President Global Channel Sales (Photo: Business Wire) Howes is responsible for leading Infovista’s indirect go-to-market strategy for all products. Howes, an accomplished channel leader with a long history of managing high-performance channel and business development teams, has expertise spanning multiple geographies in both service provider and enterprise end user environments. Prior to joining Infovista, Howes built channels for Junipe
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme